A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma

Abstract Background Extramedullary disease usually implies a dismal outcome in relapsed/refractory multiple myeloma patients, and requires novel treatment approaches. We designed a trial using Selinexor, a nuclear export protein 1 inhibitor, together with anti-B cell maturation antigen (BCMA) chimer...

Full description

Bibliographic Details
Main Authors: Di Wang, Haiying Fu, Yimei Que, Haitao Ruan, Menglei Xu, Xiaolu Long, Qiuxia Yu, Chunhui Li, Zhe Li, Songbai Cai, Wei Chen, Cong Sun, Guang Hu, Shuai Wang, Donggou He, Jianming Mei, Wen Wang, Chunrui Li
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Journal of Translational Medicine
Subjects:
CAR-T
Selinexor
B cell maturation antigen
Extramedullary Multiple Myeloma
Online Access:https://doi.org/10.1186/s12967-023-04655-w

Internet

https://doi.org/10.1186/s12967-023-04655-w

Similar Items